Lifestyle Intervention in Patients With Metastatic Prostate Cancer

Prostate Cancer Clinical Trial

— ACTIDIET-PRO  

Official title:

A Pilot Study to Investigate the Effects of Lifestyle Intervention on Physical Activity and Diet in Patients With Metastatic Prostate Cancer Receiving Novel Hormonal Agents: the ACTIDIET-PRO Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05850182
• Other study ID #: ACTIDIET-PRO
• Status: Recruiting
• Phase: N/A
• Start date: November 27, 2023
• Est. completion date: December 31, 2025

Study information

• Verified date: April 2024
• Source: Oncology Institute of Southern Switzerland
• Contact: Ursula Vogl, MD
• Phone: +41 91 811 84 63
• Email: ursula.vogl[@]eoc.ch
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The proposed pilot study aims at determining the feasibility of a lifestyle intervention including adherence to a personalised dietary regimen combined with regular physical activity in patients newly diagnosed with prostate cancer under androgen deprivation therapy.

Description:

Prostate cancer (PCa) is among the most frequent tumor types and is the second deadliest type of cancer in men. PCa has a multifactorial aetiology; modifiable environmental factors, including diet and obesity, have been associated with prostate carcinogenesis. Furthermore, patients with PCa are treated with androgen deprivation therapy (ADT), which has negative effects on the cardiovascular system and body composition, particularly on the fat and muscle mass, bone health and psychological wellbeing. Data in the current literature suggests that a lifestyle intervention e.g. with targeted and supervised exercise therapy or a dietary intervention with a prudent dietary patternmay positively influence the quality of life and the course of the disease of patients under ADT. However, conclusive data is missing. The proposed pilot study aims at determining the feasibility and the effect of a lifestyle intervention including adherence to a personalised dietary regimen combined with regular physical activity in patients newly diagnosed with PCa under ADT.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: December 31, 2025
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Written informed consent according to ICH/GCP regulations before registration.
• Age = 18 years
• Histology of adenocarcinoma of the prostate
• Patients with PCa receiving ADT alone or ADT+NHT (abiraterone, enzalutamide, apalutamide or darolutamide)
• Rising PSA (two consecutively rising PSA levels > 25% above nadir at least three weeks apart), with no evidence of clinical or radiographic progression on instrumental evaluation
• PSA doubling time > 8 weeks
• Continuation of ongoing systemic treatment is deemed feasible by treating physician

Exclusion Criteria:

• Ongoing treatment with docetaxel, cabazitaxel, radionuclides or investigational treatments
• Evidence of clinical progression or progression of disease on imaging
• Bone metastases excluding the safety of physical exercise
• Prior confirmed severe osteoporosis or other diseases affecting the bone with history of fractures
• Clinically significant cardiovascular disease (i.e. myocardial infarction within 6 months before screening; uncontrolled angina within 3 months before screening; congestive heart failure New York Heart Association class 3 or 4; history of clinically significant arrhythmias; uncontrolled hypertension indicated by systolic blood pressure > 170 mm Hg or diastolic blood pressure > 105 mm Hg at screening)
• Clinically significant chronic obstructive pulmonary disease
• Any concurrent disease or comorbid condition that interferes with the ability of the patient to participate in the study

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Behavioral:
• Lifestyle intervention
12-week lifestyle intervention including adherence to a personalized balanced dietary regimen (low total fat, low saturated fat, high ?3 fatty acids, optimized protein content, low simple sugars) combined with regular physical activity (including physiotherapy sessions and self-training).

Locations

Country	Name	City	State
Switzerland	Oncology Institute of Southern Switzerland (IOSI)	Bellinzona

Sponsors (1)

Lead Sponsor	Collaborator
Oncology Institute of Southern Switzerland

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Patient initiation rate	Study initiation rate (total number of patients enrolled divided by the number of patients screened for the study)	12 weeks
Primary	Patient retention rate	Retention rate (number of patients completing the study divided by total number of patients enrolled at baseline)	12 weeks
Primary	Adherence to prescribed training program	Adherence rate (fraction of scheduled physical activity appointments/selftrainings attended/carried out by the patients)	12 weeks
Primary	Adherence to prescribed dietary regimen	Adherence rate (fraction of days of adherence to the prescribed dietary regimen)	12 weeks
Secondary	Effect of lifestyle intervention on PSA progression	Percentage of PSA non-progressors (patients with <25% PSA rise compared to baseline) at weeks 8, 12 and 24	24 weeks
Secondary	Effect of lifestyle intervention on PSA levels	PSA doubling time calculated with the formula PSA doubling time = ln (2) / PSA Slope [PSA Slope = (ln (PSA level 2) - ln (PSA level 1)) / Time (no. of months)]	24 weeks
Secondary	Effect of lifestyle intervention on radiographic progression	Percentage of patients being free of radiographic progression according to PCWG3 at weeks 12 and 24	24 weeks
Secondary	Effect of lifestyle intervention on patient-reported quality of life	Change in patient-reported quality of life from baseline using Functional Assessment of Cancer Therapy - Prostate (FACT-P) scoring from baseline to weeks 8, 12 and 24	24 weeks
Secondary	Effect of lifestyle intervention on patient-reported fatigue	Change in patient-reported fatigue from baseline using FACIT Fatigue scoring from baseline to weeks 8, 12 and 24	24 weeks
Secondary	Effect of lifestyle intervention on time to subsequent treatment	Time to a subsequent line of treatment (in weeks)	24 months
Secondary	Effect of lifestyle intervention on plasma lipid signature	Concentration of individual lipid types in the plasma of participating patients, change compared to baseline	8 weeks
Secondary	Effect of lifestyle intervention on plasma immune signature	Concentration of inflammatory cytokines in the plasma of participating patients, change compared to baseline	8 weeks
Secondary	Effect of lifestyle intervention on microbiome composition	Differences in community diversity and/or abundance of specific bacterial taxa within the intestinal microbiome prior to or during the lifestyle intervention.	8 weeks
Secondary	Effect of lifestyle intervention on anthropometric variables	Measurement of patient height and body weight and calculation of body-mass index (BMI) at baseline, during and after the lifesyle intervention.	24 weeks
Secondary	Effect of lifestyle intervention on lean body mass	Measurement of the percentage of lean body mass by bioelectrical impedance vector analysis and by magnetic resonance imaging.	12 weeks
Secondary	Effect of lifestyle intervention on fat body mass	Measurement of the percentage of fat body mass by bioelectrical impedance vector analysis and by magnetic resonance imaging.	12 weeks